100
Million patients in the EU and the US has nail fungus
76 %
Of the patients become fungus-free in phase 3 for MOB-015
13
MOB-015 has market approval in 13 EU countries
1
Terclara® is the market leader in Sweden and Norway
Intervju med VD Anna Ljung

Interview with CEO Anna Ljung

“I am incredibly proud that we now have an approved drug in 13 EU markets and have initiated its launch in Sweden and Norway. With Terclara®, we have the opportunity to make a real difference for millions of people suffering from nail fungus worldwide and at the same time create value for our shareholders.”

Anna Ljung, CEO
Link to video from
11 november 2025
signpost quote

Our business model means lower development risk and greater opportunities to reach the market quickly than traditional drug development.

Read more

Further links